Rosalind Advisors Inc. Decreases Position in InspireMD, Inc. (NYSE:NSPR)

Rosalind Advisors Inc. lessened its position in shares of InspireMD, Inc. (NYSE:NSPR) by 0.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,495,783 shares of the company’s stock after selling 18,263 shares during the period. InspireMD accounts for 3.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 13th largest position. Rosalind Advisors Inc. owned about 9.57% of InspireMD worth $6,564,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Parkman Healthcare Partners LLC purchased a new position in shares of InspireMD during the 3rd quarter valued at about $279,000. Essex Investment Management Co. LLC purchased a new position in shares of InspireMD in the fourth quarter valued at about $191,000. Legato Capital Management LLC bought a new position in InspireMD during the 4th quarter valued at approximately $47,000. Finally, Affiance Financial LLC raised its holdings in shares of InspireMD by 2.9% during the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock valued at $497,000 after acquiring an additional 5,376 shares in the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NSPR. Lake Street Capital started coverage on InspireMD in a report on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price on the stock. StockNews.com assumed coverage on InspireMD in a research report on Tuesday. They set a “sell” rating for the company.

InspireMD Stock Performance

NSPR stock opened at $2.74 on Friday. The firm has a 50 day moving average price of $2.86 and a 200-day moving average price of $2.76. InspireMD, Inc. has a 52-week low of $1.81 and a 52-week high of $3.80. The firm has a market capitalization of $81.35 million, a price-to-earnings ratio of -3.65 and a beta of 0.88.

InspireMD Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.